(2S)-1-(Chloroacetyl)-2-Pyrrolidinecarbonitrile CAS 207557-35-5 Purity ≥99.0% (HPLC) Factory

Name: (2S)-1-(Chloroacetyl)-2-Pyrrolidinecarbonitrile  CAS: 207557-35-5 Appearance: Off-White to White Crystalline Powder Purity: ≥99.0% (HPLC) Intermediate of API (CAS: 274901-16-5) in the treatment of Type 2 Diabetes Mellitus (T2DM)  Inquiry: alvin@ruifuchem.com

Products Details

Chemical Properties:

Package: Bottle, Aluminum foil bag, 25kg/Cardboard drum, or according to customer's requirement Storage Condition: Store in sealed containers at cool and dry place; Protect from light & moistureManufacturer Supply Related Intermediates: CAS: 274901-16-5 3-Amino-1-Adamantanol CAS: 702-82-9 L-Prolinamide CAS: 7531-52-4 Boc-L-Proline CAS: 15761-39-4 (2S)-1-(Chloroacetyl)-2-Pyrrolidinecarbonitrile CAS: 207557-35-5
Item Specifications
Appearance Off-White to White Crystalline Powder
Identification  RT Conform to Standard (HPLC)
Purity / Analysis Method ≥99.0% (HPLC)
Specific Rotation [α]D20 -1.505° ~ -1.550° (C: 1.00g/100mL; CHCl3)
Melting Point 64.0~68.0℃
Loss on Drying ≤0.50%
Residue on ignition ≤0.50%
Max. Unknown Impurity ≤0.50% (HPLC) 
Total Impurities ≤1.00% (HPLC)
Test Standard Enterprise Standard
Usage Pharmaceutical Intermediates

Description:

Specifications:

Package & Storage:

Chemical Name (2S)-1-(Chloroacetyl)-2-Pyrrolidinecarbonitrile
Synonyms (S)-1-(Chloroacetyl)-2-Pyrrolidinecarbonitrile; (S)-1-(2-Chloroacetyl)pyrrolidine-2-Carbonitrile; (2S)-N-Chloroacetyl-2-Cyanotetrahydropyrrole;(S)-2-Pyrrolidinecarboxamide 
CAS Number 207557-35-5
CAT Number RF-PI104
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C7H9ClN2O
Molecular Weight 172.61
Brand Ruifu Chemical

Advantages:

FAQ:

Application:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of (2S)-1-(Chloroacetyl)-2-Pyrrolidinecarbonitrile (CAS: 207557-35-5) with high quality, it is an intermediate typically in the synthesis of API (CAS: 274901-16-5), which was developed by Novartis Pharmaceutical Co., Ltd, is another oral administrated inhibitor of Dipeptidyl peptidase-IV after Sitagliptin. In 2008, it is approved for marketing in the European Union for the treatment of type 2 diabetes.  

Contact us

Please feel free to give your inquiry in the form below We will reply you in 24 hours